Ozempic and Wegovy are both semaglutide, made by Novo Nordisk. Same drug, same injection sites, same side effects. The differences come down to dose, indication, and insurance coverage.
The headline difference
| Ozempic | Wegovy | |
|---|---|---|
| Generic | semaglutide | semaglutide |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Max dose | 2 mg / week | 2.4 mg / week |
| Average weight loss | 6–14% (off-label) | ~15% |
| CV outcomes | Approved for T2D + CVD (SUSTAIN-6) | Approved for obesity + CVD (SELECT) |
| List price | ~$969/mo | ~$1,349/mo |
Why two brands for the same drug?
When semaglutide’s weight-loss effect proved substantial in trials, Novo Nordisk pursued a separate FDA approval at a higher maximum dose (2.4 mg vs 2 mg). That higher dose became Wegovy. Branding them separately let Novo price them differently, run separate ad campaigns, and — practically — let insurance plans cover one indication but not the other.
Which one should you take?
- You have type 2 diabetes: Ozempic. It’s the labeled indication and will be covered.
- You have obesity without diabetes: Wegovy. Ozempic is technically off-label for weight loss; coverage and supply both favor Wegovy.
- You have both: Either works. Insurance usually determines the answer.
Are they interchangeable?
Pharmacologically, yes. Clinicians sometimes switch patients between them based on supply or coverage. But pen devices and dosing increments differ, and you cannot mix-and-match doses — Wegovy’s 2.4 mg dose is not available in an Ozempic pen.
See also
- Zepbound vs Wegovy — if you’re choosing between the two leading weight-loss options.
- Mounjaro vs Ozempic — the tirzepatide alternative for diabetes.
- Full Wegovy review
- Full Ozempic review
- How to get a GLP-1 prescription
- Are GLP-1s safe?